1887

Journal of Medical Microbiology logo

Volume 66, Issue 12

infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126 Free

Abstract

Data regarding the incidence and molecular epidemiology of infections (CDIs) in Greece are limited.

A retrospective study of all laboratory-confirmed CDI cases in a university hospital during a 9-month period. Stool samples from inpatients with diarrhoea were tested with a combined glutamate dehydrogenase (GDH) and toxin enzyme immunoassay (EIA) test, as part of a two-step algorithm for CDI testing. All GDH-positive samples were cultured and isolates were further tested for the presence of toxin genes and characterized by PCR ribotyping.

The incidence of CDI in our hospital was 25 per 10 000 hospital admissions. Of 33 CDI cases, 72.7 % were hospital-acquired. Fourteen different PCR ribotypes were identified, of which 017 (21.2 %), 078/126 (15.1 %) and RT202 and RT106 (9 %) were the most prevalent. Most patients had a risk profile of recent antibiotic use, older age and comorbidities. Despite mild CDI clinical characteristics, six cases showed complications and led to 18.2 % mortality.

The CDI incidence was comparable to that in other European countries. The hypervirulent PCR ribotype 027 was not found, whereas ribotypes 017 and 126 predominated. Most CDI cases were in patients who used antibiotics, emphasizing that antimicrobial stewardship should be considered as a cornerstone for the prevention of CDI.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antibiotics , Clostridium difficile , diarrhoea , epidemiology , risk factors and toxin genes
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000623
2017-12-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/12/1774.html?itemId=/content/journal/jmm/10.1099/jmm.0.000623&mimeType=html&fmt=ahah

References

  1. Kachrimanidou M, Malisiovas N. Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 2011; 37:178–187 [View Article][PubMed]
     [Google Scholar]
  2. Gabriel L, Beriot-Mathiot A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect 2014; 88:12–21 [View Article][PubMed]
     [Google Scholar]
  3. Chen Y, Glass K, Liu B, Riley TV, Korda R et al. A population-based longitudinal study of Clostridium difficile infection-related hospitalization in mid-age and older Australians. Epidemiol Infect 2017; 145:575–582 [View Article][PubMed]
     [Google Scholar]
  4. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014; 14:1208–1219 [View Article][PubMed]
     [Google Scholar]
  5. van Dorp SM, Kinross P, Gastmeier P, Behnke M, Kola A et al. Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013. Euro Surveill 2016; 21:29 [View Article][PubMed]
     [Google Scholar]
  6. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431–455 [View Article][PubMed]
     [Google Scholar]
  7. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011–1019 [View Article][PubMed]
     [Google Scholar]
  8. Arriola V, Tischendorf J, Musuuza J, Barker A, Rozelle JW et al. Assessing the risk of hospital-acquired Clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol 2016; 37:1408–1417 [View Article][PubMed]
     [Google Scholar]
  9. Skoutelis A, Pefanis A, Tsiodras S, Sipsas NV, Lelekis M et al. Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. PLoS One 2017; 12:e0182799 [View Article][PubMed]
     [Google Scholar]
  10. Saad RJ, Rao SS, Koch KL, Kuo B, Parkman HP et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol 2010; 105:403–411 [View Article][PubMed]
     [Google Scholar]
  11. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478–498 [View Article][PubMed]
     [Google Scholar]
  12. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases European Society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20:1–26 [View Article][PubMed]
     [Google Scholar]
  13. Griffiths D, Fawley W, Kachrimanidou M, Bowden R, Crook DW et al. Multilocus sequence typing of Clostridium difficile . J Clin Microbiol 2010; 48:770–778 [View Article][PubMed]
     [Google Scholar]
  14. Lemee L, Dhalluin A, Pestel-Caron M, Lemeland JF, Pons JL. Multilocus sequence typing analysis of human and animal Clostridium difficile isolates of various toxigenic types. J Clin Microbiol 2004; 42:2609–2617 [View Article][PubMed]
     [Google Scholar]
  15. Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile . Gene 1996; 181:29–38 [View Article][PubMed]
     [Google Scholar]
  16. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile . FEMS Microbiol Lett 2000; 186:307–312 [View Article][PubMed]
     [Google Scholar]
  17. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER et al. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007; 13:1058–1064 [View Article][PubMed]
     [Google Scholar]
  18. Fawley WN, Knetsch CW, MacCannell DR, Harmanus C, Du T et al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile . PLoS One 2015; 10:e0118150 [View Article][PubMed]
     [Google Scholar]
  19. Rodríguez-Pardo D, Almirante B, Bartolomé RM, Pomar V, Mirelis B et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol 2013; 51:1465–1473 [View Article][PubMed]
     [Google Scholar]
  20. Taori SK, Wroe A, Hardie A, Gibb AP, Poxton IR. A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections. J Infect 2014; 69:134–144 [View Article][PubMed]
     [Google Scholar]
  21. Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen CH et al. Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina. Clin Microbiol Infect 2009; 15:1080–1086 [View Article][PubMed]
     [Google Scholar]
  22. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E et al. European study group on Clostridium difficile (ESGCD). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007; 13:1048–1057 [Crossref]
     [Google Scholar]
  23. Pituch H, Brazier JS, Obuch-Woszczatynski P, Wultanska D, Meisel-Mikolajczyk F et al. Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance. J Med Microbiol 2006; 55:207–213 [View Article][PubMed]
     [Google Scholar]
  24. Dobreva EG, Ivanov IN, Vathcheva-Dobrevska RS, Ivanova KI, Asseva GD et al. Advances in molecular surveillance of Clostridium difficile in Bulgaria. J Med Microbiol 2013; 62:1428–1434 [View Article][PubMed]
     [Google Scholar]
  25. Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G. Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro Surveill 2009; 14:pii=19403 [View Article][PubMed]
     [Google Scholar]
  26. Goorhuis A, van der Kooi T, Vaessen N, Dekker FW, van den Berg R et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007; 45:695–703 [View Article][PubMed]
     [Google Scholar]
  27. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013; 173:1359–1367 [View Article][PubMed]
     [Google Scholar]
  28. Cairns MD, Preston MD, Hall CL, Gerding DN, Hawkey PM et al. Comparative genome analysis and global phylogeny of the toxin variant Clostridium difficile PCR ribotype 017 reveals the evolution of two independent sublineages. J Clin Microbiol 2017; 55:865–876 [View Article][PubMed]
     [Google Scholar]
  29. Schneeberg A, Neubauer H, Schmoock G, Baier S, Harlizius J et al. Clostridium difficile genotypes in piglet populations in Germany. J Clin Microbiol 2013; 51:3796–3803 [View Article][PubMed]
     [Google Scholar]
  30. Alcalá L, Reigadas E, Marín M, Fernández-Chico A, Catalán P et al. Comparison of genomera C. difficile and Xpert C. difficile as confirmatory tests in a multistep algorithm for diagnosis of Clostridium difficile infection. J Clin Microbiol 2015; 53:332–335 [View Article][PubMed]
     [Google Scholar]
  31. Davies KA, Ashwin H, Longshaw CM, Burns DA, Davis GL et al. Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill 2016; 21: [View Article][PubMed]
     [Google Scholar]
  32. Søes LM, Brock I, Persson S, Simonsen J, Pribil Olsen KE et al. Clinical features of Clostridium difficile infection and molecular characterization of the isolated strains in a cohort of Danish hospitalized patients. Eur J Clin Microbiol Infect Dis 2012; 31:185–192 [View Article][PubMed]
     [Google Scholar]
  33. Silva Júnior M. Recent changes in Clostridium difficile infection. Einstein 2012; 10:105–109 [View Article][PubMed]
     [Google Scholar]
  34. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 2014; 7:63–72 [View Article][PubMed]
     [Google Scholar]
  35. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951–1961 [View Article][PubMed]
     [Google Scholar]
  36. Hota SS, Achonu C, Crowcroft NS, Harvey BJ, Lauwers A et al. Determining mortality rates attributable to Clostridium difficile infection. Emerg Infect Dis 2012; 18:305–307 [View Article][PubMed]
     [Google Scholar]
  37. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037–1042 [View Article][PubMed]
     [Google Scholar]
  38. Mitchell BG, Gardner A. Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 2012; 1:20 [View Article][PubMed]
     [Google Scholar]
  39. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014; 9:e98400 [View Article][PubMed]
     [Google Scholar]
  40. Wilson V, Cheek L, Satta G, Walker-Bone K, Cubbon M et al. Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis 2010; 50:e77-81 [View Article][PubMed]
     [Google Scholar]
  41. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363–372 [View Article][PubMed]
     [Google Scholar]
  42. Warny M, Pepin J, Fang A, Killgore G, Thompson A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079–1084 [View Article][PubMed]
     [Google Scholar]
  43. Arroyo LG, Kruth SA, Willey BM, Staempfli HR, Low DE et al. PCR ribotyping of Clostridium difficile isolates originating from human and animal sources. J Med Microbiol 2005; 54:163–166 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000623
Loading
Clostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126
J. Med. Microbiol. 66, 1774 (2017); https://doi.org/10.1099/jmm.0.000623
/content/journal/jmm/10.1099/jmm.0.000623
/content/journal/jmm/10.1099/jmm.0.000623
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error